

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Verreck et al. Confirmation No.: 2459
Appln. No. : 10/088,805
Filed : March 21, 2002
Title : ANTIVIRAL COMPOSITIONS
Art Unit : 1618
Examiner : Jake Minh Vu

I hereby certify that this correspondence is being filed
electronically with the U.S. Patent Office on:

October 6, 2006

(Date of Deposit)

Laura A. Donnelly

(Name of applicant, assignee, or Registered Representative)

/Laura A. Donnelly/

(Signature)

October 6, 2006

(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Dear Sir:

The owner, Janssen Pharmaceutica, NV of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term of any patent granted on pending Application No. 11/111,400, filed on April 21,

2005, as such term is defined in U.S.C. 154 and 173, and as the term of any patent granted on said Application No. 11/111,400 may be shortened by an terminal disclaimer filed prior to the patent on the pending 11/111,400 application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the 11/111,400 application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate:

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby certify that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record.

Respectfully submitted,

/Laura A. Donnelly/

By: _____
Laura A. Donnelly
Reg. No. 38,435

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1729
Dated: October 6, 2006

☒ The Terminal Disclaimer fee of \$130.00 and any additional fees which may be owed in connection with the filing of this Terminal Disclaimer can be charged to Johnson & Johnson Deposit Account No. 10-0750/JAB-1531-USPCT/LAD. Three copies of this sheet are enclosed.